ReviewFrontiers in immunology2026
Intratumoral microbiota: bidirectional modulation of tumor radiosensitivity.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The term "intratumoral microbiota" refers to the microbial communities that reside within tumor tissues, including bacteria, fungi, mycoplasma, and viruses. Accumulating evidence indicates that the intratumoral microbiota is closely associated with tumor initiation and progression. Nevertheless, the impact of these microbes on radiotherapy outcomes remains largely unexplored. In this review, we discussed how the intratumoral microbiota influences radiation response, highlighting the diverse mechanisms through which microbial communities modulate tumor cell behavior. Specifically, intratumoral microbes may confer radioresistance by enhancing DNA damage repair, reprogramming core metabolic pathways, regulating the cell cycle, and modulating autophagy, thereby diminishing radiotherapy efficacy. Conversely, certain microorganisms can enhance radiosensitivity by directly inducing DNA damage in host tumor cells, activating antitumor immune responses, or elevating intracellular reactive oxygen species(ROS) levels, thereby amplifying radiation-induced cytotoxicity. Additionally, microbial aggravation of tumor hypoxia may further diminish radiosensitivity by creating a more radioresistant tumor microenvironment. Therefore, the regulatory role of the intratumoral microbiota in radiotherapy sensitivity provides a novel direction for cancer therapy. Strategies that precisely target the intratumoral microbiota hold promise as important approaches for overcoming radioresistance and improving treatment outcomes in patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.